Multiple companies are developing kallikrein inhibitor therapies for various routes of delivery to provide an alternative treatment for patients with diabetic macular edema rather than the traditional treatment of anti-VEGF injections.
Approximately half of patients with DME are not optimal responders to anti-VEGF injections to treat their disease. Companies are developing treatments to improve efficacy and sustainability of therapy for patients who do not satisfactorily respond to anti-VEGF injections, OSN Retina/Vitreous Board Member Pravin U. Dugel, MD, said.
“There are a lot of
Uncategorized